Zacks Research upgraded shares of Oxford BioMedica (OTCMKTS:OXBDF – Free Report) to a hold rating in a research report report published on Wednesday morning,Zacks.com reports.
Oxford BioMedica Price Performance
OXBDF stock opened at $8.00 on Wednesday. Oxford BioMedica has a 12 month low of $5.17 and a 12 month high of $12.61. The company has a 50-day moving average price of $8.06 and a 200 day moving average price of $8.93.
Oxford BioMedica Company Profile
Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.
In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.
Further Reading
- Five stocks we like better than Oxford BioMedica
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
